Outcome of immunotherapy in adrenocortical carcinoma

• Verfasst von: Remde, Hanna [VerfasserIn]
• Verfasst von: Schmidt-Pennington, Laura [VerfasserIn]
• Verfasst von: Reuter, Miriam [VerfasserIn]
• Verfasst von: Landwehr, Laura-Sophie [VerfasserIn]
• Verfasst von: Jensen, Marie [VerfasserIn]
• Verfasst von: Lahner, Harald [VerfasserIn]
• Verfasst von: Kimpel, Otilia [VerfasserIn]
• Verfasst von: Altieri, Barbara [VerfasserIn]
• Verfasst von: Laubner, Katharina [VerfasserIn]
• Verfasst von: Schreiner, Jochen [VerfasserIn]
• Verfasst von: Bojunga, Joerg [VerfasserIn]
• Verfasst von: Kircher, Stefan [VerfasserIn]
• Verfasst von: Kunze, Catarina Alisa [VerfasserIn]
• Verfasst von: Pohrt, Anne [VerfasserIn]
• Verfasst von: Teleanu, Maria-Veronica [VerfasserIn]
• Verfasst von: Hübschmann, Daniel [VerfasserIn]
• Verfasst von: Stenzinger, Albrecht [VerfasserIn]
• Verfasst von: Glimm, Hanno [VerfasserIn]
• Verfasst von: Fröhling, Stefan [VerfasserIn]
• Verfasst von: Fassnacht, Martin [VerfasserIn]
• Verfasst von: Mai, Knut [VerfasserIn]
• Verfasst von: Kroiss, Matthias [VerfasserIn]
• Titel: Outcome of immunotherapy in adrenocortical carcinoma
• Titelzusatz: a retrospective cohort study
• Verf.angabe: Hanna Remde, Laura Schmidt-Pennington, Miriam Reuter, Laura-Sophie Landwehr, Marie Jensen, Harald Lahner, Otilia Kimpel, Barbara Altieri, Katharina Laubner, Jochen Schreiner, Joerg Bojunga, Stefan Kircher, Catarina Alisa Kunze, Anne Pohrt, Maria-Veronica Teleanu, Daniel Hübschmann, Albrecht Stenzinger, Hanno Glimm, Stefan Fröhling, Martin Fassnacht, Knut Mai, and Matthias Kroiss
• E-Jahr: 2023
• Jahr: June 2023
• Umfang: 9 S.
• Illustrationen: Illustrationen
• Fussnoten: Veröffentlicht: 01. Juni 2023 ; Gesehen am 27.07.2023
• Titel Quelle: Enthalten in: European journal of endocrinology
• Ort Quelle: Oxford : Oxford University Press, 1948
• Jahr Quelle: 2023
• Band/Heft Quelle: 188(2023), 6 vom: Juni, Seite 485-493
• ISSN Quelle: 1479-683X
• DOI: doi:10.1093/ejendo/lvad054
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1853779326

Abstract

Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a real-life setting.Retrospective cohort study of 54 patients with advanced ACC receiving ICI as compassionate use at 6 German reference centres between 2016 and 2022.Objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAE) were assessed.In 52 patients surviving at least 4 weeks after initiation of ICI, ORR was 13.5% (6-26) and DCR was 24% (16-41). PFS was 3.0 months (95% CI, 2.3-3.7). In all patients, median OS was 10.4 months (3.8-17). 17 TRAE occurred in 15 patients, which was associated with a longer PFS of 5.5 (1.9-9.2) vs 2.5 (2.0-3.0) months (HR 0.29, 95% CI, 0.13-0.66, P = 0.001) and OS of 28.2 (9.5-46.8) vs 7.0 (4.1-10.2) months (HR 0.34, 95% CI, 0.12-0.93). Positive tissue staining for programmed cell death ligand 1 (PD-L1) was associated with a longer PFS of 3.2 (2.6-3.8) vs 2.3 (1.6-3.0, P < 0.05) months. Adjusted for concomitant mitotane use, treatment with nivolumab was associated with lower risk of progression (HR 0.36, 0.15-0.90) and death (HR 0.20, 0.06-0.72) compared to pembrolizumab.In the real-life setting, we observe a response comparable to other second-line therapies and an acceptable safety profile in ACC patients receiving different ICI. The relevance of PD-L1 as a marker of response and the potentially more favourable outcome in nivolumab-treated patients require confirmation.